• Publications
  • Influence

Claim Your Author Page
Ensure your research is discoverable on Semantic Scholar. Claiming your author page allows you to personalize the information displayed and manage publications (all current information on this profile has been aggregated automatically from publisher and metadata sources).
  • Jean-Luc Harousseau, Hérvé Avet-Loiseau, +14 authors Philippe Moreau
  • Medicine
  • Journal of clinical oncology : official journal…
  • 2009 (First Publication: 1 December 2009)
  • PURPOSE The prognostic impact of complete response (CR) achievement in multiple myeloma (MM) has been shown mostly in the context of autologous stem-cell transplantation. Other levels of responseContinue Reading
  • Laurent Garderet, Simona Iacobelli, +27 authors Goesta Gahrton
  • Medicine
  • Journal of clinical oncology : official journal…
  • 2012 (First Publication: 10 July 2012)
  • PURPOSE This prospective multicenter phase III study compared the efficacy and safety of a triple combination (bortezomib-thalidomide-dexamethasone [VTD]) versus a dual combinationContinue Reading
  • Cyrille Hulin, Thierry Facon, +12 authors Philippe Moreau
  • Medicine
  • 2007 (First Publication: 16 November 2007)
  • Background: The MP-T combination has become the standard treatment for newly diagnosed MM patients (pts) aged 65 to 75 years (Facon et al; Lancet 2007 [Epub ahead of print]). However, no specificContinue Reading
  • Michel Attal, Jean-Luc Harousseau, +15 authors Denis Caillot
  • Medicine
  • 2004 (First Publication: 16 November 2004)
  • High dose therapy (HDT) supported with autologous stem cell transplantation has been introduced in the management of myeloma. However, after a single or a double transplantation, almost all patientsContinue Reading
  • Gilles Salles, Nicolas Mounier, +14 authors Charles Foussard
  • Medicine
  • 2007 (First Publication: 16 November 2007)
  • Background. The FL2000 study evaluated the combination of the anti-CD20 monoclonal antibody rituximab with chemotherapy plus interferon in the first line treatment of follicular lymphoma patients.Continue Reading